European Companies Search Engine
EU funding (€8,857,813): Discovering the causes of three poorly understood cancers in Europe Hor 9 Dec 2022 EU Research and Innovation programme "Horizon"
Overview
Text
Discovering the causes of three poorly understood cancers in Europe
"The overall goal of DISCERN is to understand the causes of three poorly understood cancers in Europe; renal, pancreatic and colorectal cancer, and help to explain their geographical distribution, including their high incidence in central and eastern Europe. This will be achieved by combining large-scale European biorepositories comprising population-based cohorts and tumour case-series with state-of-the-art molecular profiling techniques and machine learning approaches. In particular, DISCERN will identify potential new causal risk factors for the three cancers using novel exposomics and proteomics scans, as well detailed geospatial and environmental exposure information from 16 large-scale epidemiological cohorts including almost 900,000 individuals. It will also explore biological mechanisms on how these risk factors are potentially causing these cancer types with a focus on promoting factors in normal tissues using deep sequencing, single cell multi-omics and spatial proteomics. The causal effects of identified cancer risk factors and the cellular signalling responses they trigger will be further evaluated using a panel of stem cells and colon, renal and pancreatic 3D organoids. The results from DISCERN will be disseminated to citizens, patients and policy makers through collaborating patient and participant organizations. DISCERN will provide the critical evidence base required to develop new prevention strategies to tackle the growing burden of renal, pancreatic and colorectal cancer in Europe. This action is part of the Cancer Mission cluster of projects on ""Understanding""."
Funded Companies:
| Company name | Funding amount |
| Imperial College of Science Technology and Medicine | ? |
| Centre International de Recherche sur le Cancer | €2,443,529 |
| Digestive Cancers Europe Dice | €87,500 |
| Fundacio Institut D'Investigacio Biomedica de Bellvitge | €0.00 |
| Fundacio Institut de Recerca Biomedica (Irb Barcelona) | €1,246,250 |
| Institut Catala D'Oncologia | €118,750 |
| Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement | €202,735 |
| Instituto Neurologico Mediterraneo Neuromed S.p.A. | €58,763 |
| Instytut Medycyny Pracy Imienia prof. Dra Med. Jerzego Nofera w Lodzi | €73,006 |
| Kungliga Tekniska Hoegskolan | €1,238,595 |
| Masarykova Univerzita | €772,744 |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie -Panstwowy Instytut Badawczy | €57,775 |
| Pancreatic Cancer Europe | €87,500 |
| Stichting Ikcc | €87,500 |
| Tartu Ulikool | €245,466 |
| Universita Degli Studi Di Torino | €173,946 |
| Universiteit Leiden | €1,175,425 |
| Universiteit Utrecht | €701,783 |
| Universitetet I Tromsoe - Norges Arktiske Universitet | €86,548 |
Source: https://cordis.europa.eu/project/id/101096888
The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Imperial College of Science Technology and Medicine, London.